Search

Displaying results 6881 - 6890 of 8696 in total
  1. Drug

    Amitifadine

    go.drugbank.com/drugs/DB05964
    Investigational

  2. Drug

    Technetium Tc-99m mebrofenin

    go.drugbank.com/drugs/DB09137
    ApprovedWithdrawn

    Currently available within a sterile kit, Tc-99m Mebrofenin is indicated for imaging of the liver and gallbladder.

  3. Drug

    Surovatamig

    go.drugbank.com/drugs/DB19420
    Investigational

    TNB-486 is under investigation in clinical trial NCT06564038 (A Study of AZD0486 Monotherapy or in Combination With Other Anti-cancer Agents for Mature B-cell Malignancies).

  4. Drug

    ICG-136

    go.drugbank.com/drugs/DB17343
    Experimental

    ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.

  5. Drug

    Mozafancogene autotemcel

    go.drugbank.com/drugs/DB17723
    Investigational

    RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A

  6. Drug

    Etaracizumab

    go.drugbank.com/drugs/DB12213
    Investigational

    Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.

  7. Drug

    Peldesine

    go.drugbank.com/drugs/DB02568
    Investigational

    It has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis.

  9. Drug

    DYN-101

    go.drugbank.com/drugs/DB17921
    Investigational

    DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.

  10. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.